170 related articles for article (PubMed ID: 28956330)
1. The PDE4 cAMP-Specific Phosphodiesterases: Targets for Drugs with Antidepressant and Memory-Enhancing Action.
Bolger GB
Adv Neurobiol; 2017; 17():63-102. PubMed ID: 28956330
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase-4D Knock-down in the Prefrontal Cortex Alleviates Chronic Unpredictable Stress-Induced Depressive-Like Behaviors and Memory Deficits in Mice.
Wang ZZ; Yang WX; Zhang Y; Zhao N; Zhang YZ; Liu YQ; Xu Y; Wilson SP; O'Donnell JM; Zhang HT; Li YF
Sci Rep; 2015 Jul; 5():11332. PubMed ID: 26161529
[TBL] [Abstract][Full Text] [Related]
3. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D.
Sierksma AS; van den Hove DL; Pfau F; Philippens M; Bruno O; Fedele E; Ricciarelli R; Steinbusch HW; Vanmierlo T; Prickaerts J
Neuropharmacology; 2014 Feb; 77():120-30. PubMed ID: 24067928
[TBL] [Abstract][Full Text] [Related]
4. Altered phosphorylation, electrophysiology, and behavior on attenuation of PDE4B action in hippocampus.
Campbell SL; van Groen T; Kadish I; Smoot LHM; Bolger GB
BMC Neurosci; 2017 Dec; 18(1):77. PubMed ID: 29197324
[TBL] [Abstract][Full Text] [Related]
5. The Past, Present, and Future of Phosphodiesterase-4 Modulation for Age-Induced Memory Loss.
Hansen RT; Zhang HT
Adv Neurobiol; 2017; 17():169-199. PubMed ID: 28956333
[TBL] [Abstract][Full Text] [Related]
6. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs.
Zhang HT
Curr Pharm Des; 2009; 15(14):1688-98. PubMed ID: 19442182
[TBL] [Abstract][Full Text] [Related]
7. RNA interference-mediated phosphodiesterase 4D splice variants knock-down in the prefrontal cortex produces antidepressant-like and cognition-enhancing effects.
Wang ZZ; Zhang Y; Liu YQ; Zhao N; Zhang YZ; Yuan L; An L; Li J; Wang XY; Qin JJ; Wilson SP; O'Donnell JM; Zhang HT; Li YF
Br J Pharmacol; 2013 Feb; 168(4):1001-14. PubMed ID: 23003922
[TBL] [Abstract][Full Text] [Related]
8. Targeting phosphodiesterase 4 as a potential therapeutic strategy for enhancing neuroplasticity following ischemic stroke.
Wang H; Gaur U; Xiao J; Xu B; Xu J; Zheng W
Int J Biol Sci; 2018; 14(12):1745-1754. PubMed ID: 30416389
[TBL] [Abstract][Full Text] [Related]
9. PDE4 as a target for cognition enhancement.
Richter W; Menniti FS; Zhang HT; Conti M
Expert Opin Ther Targets; 2013 Sep; 17(9):1011-27. PubMed ID: 23883342
[TBL] [Abstract][Full Text] [Related]
10. The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling.
Wang G; Chen L; Pan X; Chen J; Wang L; Wang W; Cheng R; Wu F; Feng X; Yu Y; Zhang HT; O'Donnell JM; Xu Y
Oncotarget; 2016 Apr; 7(14):17380-92. PubMed ID: 26980711
[TBL] [Abstract][Full Text] [Related]
11. Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA).
Collins DM; Murdoch H; Dunlop AJ; Charych E; Baillie GS; Wang Q; Herberg FW; Brandon N; Prinz A; Houslay MD
Cell Signal; 2008 Dec; 20(12):2356-69. PubMed ID: 18845247
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus.
Zhang HT; Zhao Y; Huang Y; Dorairaj NR; Chandler LJ; O'Donnell JM
Neuropsychopharmacology; 2004 Aug; 29(8):1432-9. PubMed ID: 15114341
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders.
Wu C; Rajagopalan S
Obes Rev; 2016 May; 17(5):429-41. PubMed ID: 26997580
[TBL] [Abstract][Full Text] [Related]
14. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase inhibitors enhance object memory independent of cerebral blood flow and glucose utilization in rats.
Rutten K; Van Donkelaar EL; Ferrington L; Blokland A; Bollen E; Steinbusch HW; Kelly PA; Prickaerts JH
Neuropsychopharmacology; 2009 Jul; 34(8):1914-25. PubMed ID: 19262466
[TBL] [Abstract][Full Text] [Related]
16. Specific Inhibition of Phosphodiesterase-4B Results in Anxiolysis and Facilitates Memory Acquisition.
McGirr A; Lipina TV; Mun HS; Georgiou J; Al-Amri AH; Ng E; Zhai D; Elliott C; Cameron RT; Mullins JG; Liu F; Baillie GS; Clapcote SJ; Roder JC
Neuropsychopharmacology; 2016 Mar; 41(4):1080-92. PubMed ID: 26272049
[TBL] [Abstract][Full Text] [Related]
17. RACK1 and β-arrestin2 attenuate dimerization of PDE4 cAMP phosphodiesterase PDE4D5.
Bolger GB
Cell Signal; 2016 Jul; 28(7):706-12. PubMed ID: 26257302
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant-like effect of etazolate, a cyclic nucleotide phosphodiesterase 4 inhibitor--an approach using rodent behavioral antidepressant tests battery.
Jindal A; Mahesh R; Gautam B; Bhatt S; Pandey D
Eur J Pharmacol; 2012 Aug; 689(1-3):125-31. PubMed ID: 22698578
[TBL] [Abstract][Full Text] [Related]
19. Discovery of N-Alkyl Catecholamides as Selective Phosphodiesterase-4 Inhibitors with Anti-neuroinflammation Potential Exhibiting Antidepressant-like Effects at Non-emetic Doses.
Zhou ZZ; Cheng YF; Zou ZQ; Ge BC; Yu H; Huang C; Wang HT; Yang XM; Xu JP
ACS Chem Neurosci; 2017 Jan; 8(1):135-146. PubMed ID: 27690383
[TBL] [Abstract][Full Text] [Related]
20. Dominant-Negative Attenuation of cAMP-Selective Phosphodiesterase PDE4D Action Affects Learning and Behavior.
Bolger GB; Smoot LHM; van Groen T
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32784895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
